(P142) Older Patients Derive Greater Benefit From Adjuvant and Neoadjuvant Radiotherapy in Diverse Solid Malignancies

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This is the largest analysis to date examining the effects of RT in a broad population of solid tumor patients. Although we were unable to control for chemotherapy use in this cohort, RT was associated with superior oncologic outcome compared with surgery alone among patients with multiple solid malignancies. This positive effect was most pronounced in older patients with breast and rectal cancer, suggesting age-dependent effects of RT.

Noah K. Yuen, MD, Arta Monjazeb, MD, PhD, Chin-Shang Li, PhD, Dariusz Borys, MD, Richard Bold, MD, Robert Canter, MD; University of California, Davis Medical Center

BACKGROUND: Radiation therapy (RT) is a standard component in the contemporary multimodality management of numerous solid malignancies. Increasing studies have shown that age-related immunologic changes may impact the bioactivity of RT. We hypothesized that outcomes of RT would be influenced by age across various solid cancers.

METHODS: Using Surveillance, Epidemiology, and End Results (SEER) data (1990–2011), we identified 959,731 adult patients (aged > 18 yr) with common nonmetastatic solid malignancies, including breast, lung, and rectal cancer, undergoing surgery ± RT. We compared patient demographics, tumor characteristics, and treatments by age. Multivariable analyses were used to examine the effect of these variables on overall survival (OS) and disease-specific survival (DSS). Hazard ratios were calculated based on multivariable Cox proportional hazards models and logistic regression analysis.

RESULTS: The study cohort consisted of 70.0% breast, 13.5% lung, 11.9% rectal, 3.4% sarcoma, and 1.2% esophageal cancer. Mean age at diagnosis was 61.1 ± 13.8 years, and 42% of patients were aged ≥ 65 years. A total of 43.2% received either adjuvant (39.0%) or neoadjuvant (4.2%) RT. With the exception of lung cancer (OS hazard ratio [HR] = 1.21; 1.19–1.23), RT was associated with improved survival in patients of all ages: breast (OS HR = 0.72; 0.71–0.73), rectal (OS HR = 0.81; 0.79–0.83), esophageal (OS HR = 0.83; 0.75–0.91), and sarcoma (OS HR = 0.63; 0.56–0.70). These positive effects were amplified in elderly patients (aged ≥ 65 yr), with breast (OS HR = 0.66; 0.65–0.66) and rectal cancers (OS HR = 0.74; 0.72–0.76) having the most benefit. On logistic regression, the HR for risk of death per year of age was lower in patients receiving RT vs those not receiving RT: breast (1.057–1.060 vs 1.072–1.074), rectal (1.043–1.048 vs 1.081–1.085), esophageal (1.006–1.023 vs 1.026–1.046), and lung cancer (1.039–1.047 vs 1.050–1.054).

CONCLUSIONS: This is the largest analysis to date examining the effects of RT in a broad population of solid tumor patients. Although we were unable to control for chemotherapy use in this cohort, RT was associated with superior oncologic outcome compared with surgery alone among patients with multiple solid malignancies. This positive effect was most pronounced in older patients with breast and rectal cancer, suggesting age-dependent effects of RT. Further investigation into the mechanism of these age-related effects is indicated.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Related Content